Modality
ADC
MOA
EZH2i
Target
VEGF
Pathway
JAK/STAT
CSUBladder Ca
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
~Aug 2018
→ ~Nov 2019
Phase 3
Feb 2020
→ Feb 2031
Phase 3Current
NCT07598392
1,583 pts·Bladder Ca
2020-07→2031-02·Completed
NCT05488817
425 pts·Bladder Ca
2020-02→2029-04·Not yet recruiting
2,008 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-04-103.0y awayPh3 Readout· Bladder Ca
2031-02-214.9y awayPh3 Readout· Bladder Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Not yet…
P3
Complet…
Catalysts
Ph3 Readout
2029-04-10 · 3.0y away
Bladder Ca
Ph3 Readout
2031-02-21 · 4.9y away
Bladder Ca
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07598392 | Phase 3 | Bladder Ca | Completed | 1583 | Safety |
| NCT05488817 | Phase 3 | Bladder Ca | Not yet recr... | 425 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |